Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
10,287
Views
9
CrossRef citations to date
0
Altmetric
Review

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches

Tushar Jaina Adimab LLC, Palo Alto, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9261-803XView further author information
ORCID Icon,
Todd Bolandb Computational Biology, Adimab LLC, Lebanon, NH, USAView further author information
&
Maximiliano Vásqueza Adimab LLC, Palo Alto, CA, USAView further author information
Article: 2200540 | Received 13 Feb 2023, Accepted 04 Apr 2023, Published online: 18 Apr 2023

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny & Laura von Schantz. (2024) RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties. mAbs 16:1.
Read now

Articles from other publishers (8)

Gemma L. Gordon, Matthew I. J. Raybould, Ashley Wong & Charlotte M. Deane. (2024) Prospects for the computational humanization of antibodies and nanobodies. Frontiers in Immunology 15.
Crossref
Leonard Wossnig, Norbert Furtmann, Andrew Buchanan, Sandeep Kumar & Victor Greiff. (2024) Best practices for machine learning in antibody discovery and development. Drug Discovery Today, pages 104025.
Crossref
Wenzhen Li, Hongyan Lin, Ziru Huang, Shiyang Xie, Yuwei Zhou, Rong Gong, Qianhu Jiang, ChangCheng Xiang & Jian Huang. (2024) DOTAD: A Database of Therapeutic Antibody Developability. Interdisciplinary Sciences: Computational Life Sciences.
Crossref
Tadeusz Satława, Mateusz Tarkowski, Sonia Wróbel, Paweł Dudzic, Tomasz Gawłowski, Tomasz Klaus, Marek Orłowski, Anna Kostyn, Sandeep Kumar, Andrew Buchanan & Konrad Krawczyk. (2024) LAP: Liability Antibody Profiler by sequence & structural mapping of natural and therapeutic antibodies. PLOS Computational Biology 20:3, pages e1011881.
Crossref
Maxime Lecerf, Robin V. Lacombe & Jordan D. Dimitrov. (2023) Polyreactivity of antibodies from different B-cell subpopulations is determined by distinct sequence patterns of variable region. Frontiers in Immunology 14.
Crossref
Paul Arras, Han Byul Yoo, Lukas Pekar, Thomas Clarke, Lukas Friedrich, Christian Schröter, Jennifer Schanz, Jason Tonillo, Vanessa Siegmund, Achim Doerner, Simon Krah, Enrico Guarnera, Stefan Zielonka & Andreas Evers. (2023) AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study. Frontiers in Molecular Biosciences 10.
Crossref
Joschka Bauer, Nandhini Rajagopal, Priyanka Gupta, Pankaj Gupta, Andrew E. Nixon & Sandeep Kumar. (2023) How can we discover developable antibody-based biotherapeutics?. Frontiers in Molecular Biosciences 10.
Crossref
Igor Jaszczyszyn, Weronika Bielska, Tomasz Gawlowski, Pawel Dudzic, Tadeusz Satława, Jarosław Kończak, Wiktoria Wilman, Bartosz Janusz, Sonia Wróbel, Dawid Chomicz, Jacob D. Galson, Jinwoo Leem, Sebastian Kelm & Konrad Krawczyk. (2023) Structural modeling of antibody variable regions using deep learning—progress and perspectives on drug discovery. Frontiers in Molecular Biosciences 10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.